NEW DELHI: A total of 447 adverse events were reported following immunization against Covid-19 during the first two days of the vaccination campaign. While only three cases were initially hospitalized, two have already been discharged from AIIMS, New Delhi and Northern Railway Hospital, respectively, the Health Ministry said.
“One case is still under observation at AIIMS Rishikesh and it is fine,” said Additional Health Secretary Manohar Agnani.
Most of the adverse events reported so far are mild such as fever, pain, headache, nausea, dizziness, and mild allergic reactions such as rashes, etc.
“There are protocols for notification, immediate case management at the site of the vaccination session, transportation and hospitalization, and the additional care of such cases. There are also protocols for systematic investigation and causation assessment of severe AEFIs, ”Agnani said.
A worker from the Indian Institute of Medical Sciences (AIIMS) was admitted to a hospital when he developed an allergic reaction after receiving the Covaxin vaccine on Saturday.
An adverse event after vaccination (AEFI) is defined as any unexpected medical event that follows vaccination. It may or may not be related to the vaccine or the vaccination process.
India launched its first phase of the Covid vaccination program across the country on Saturday with two vaccines: The University of Oxford and AstraZeneca developed Covishield and Covaxin from Bharat Biotech, developed in collaboration with the Indian Council for Medical Research.
Although 110 crore doses of Covishield, manufactured locally by the Serum Institute of India based in Pune, have been distributed in all states and UT, 12 states have also received Covaxin.
So far, a total of 2,24,301 beneficiaries have been vaccinated. On Sunday, 17,072 beneficiaries were vaccinated in 553 sessions in six states. The government said states have been advised to schedule 4-day-a-week Covid vaccination sessions to minimize disruption to routine health services.
“One case is still under observation at AIIMS Rishikesh and it is fine,” said Additional Health Secretary Manohar Agnani.
Most of the adverse events reported so far are mild such as fever, pain, headache, nausea, dizziness, and mild allergic reactions such as rashes, etc.
“There are protocols for notification, immediate case management at the site of the vaccination session, transportation and hospitalization, and the additional care of such cases. There are also protocols for systematic investigation and causation assessment of severe AEFIs, ”Agnani said.
A worker from the Indian Institute of Medical Sciences (AIIMS) was admitted to a hospital when he developed an allergic reaction after receiving the Covaxin vaccine on Saturday.
An adverse event after vaccination (AEFI) is defined as any unexpected medical event that follows vaccination. It may or may not be related to the vaccine or the vaccination process.
India launched its first phase of the Covid vaccination program across the country on Saturday with two vaccines: The University of Oxford and AstraZeneca developed Covishield and Covaxin from Bharat Biotech, developed in collaboration with the Indian Council for Medical Research.
Although 110 crore doses of Covishield, manufactured locally by the Serum Institute of India based in Pune, have been distributed in all states and UT, 12 states have also received Covaxin.
So far, a total of 2,24,301 beneficiaries have been vaccinated. On Sunday, 17,072 beneficiaries were vaccinated in 553 sessions in six states. The government said states have been advised to schedule 4-day-a-week Covid vaccination sessions to minimize disruption to routine health services.
.
